This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
A new preprint design is coming!
We have improved readability, clarity, accessibility, and opportunities for engagement.
Research article
Yuejun Huang
Second Affiliated Hospital of Shantou University Medical College
Corresponding Author
ORCiD: https://orcid.org/0000-0001-8240-5738
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background The effects of maternal antenatal corticosteroid (ACS) treatment on the short-term outcome of late preterm infants are unclear.
Methods This is a retrospective cohort study. Data of pregnant women who gave birth between 34 (0/7) to 36 (6/7) weeks gestation from January 2014 to June 2019 were collected. Nine short-term outcomes of preterm infants from mothers who received ACS treatment were compared to preterm infants from mothers who did not receive ACS treatment.
Results The results were as follows: (1) ACS administration to pregnant women at high risk for giving birth between 34 (0/7) to 36 (6/7) weeks pregnancy, can decrease the cost and inpatient time of their infants; (2) lack of maternal ACS treatment is an independent risk factor for neonatal respiratory distress syndrome; (3) use of maternal ACS does not increase the risk of neonatal pneumonia, neonatal hypoglycemia, neonatal sepsis, necrotizing enterocolitis of newborns, neonatal intracranial hemorrhage, and hypoxic-ischemic encephalopathy in preterm infants.
Conclusions Use of ACS for pregnant women at risk for giving birth between 34 (0/7) to 36 (6/7) weeks pregnancy has more advantage than disadvantage. Our study provides evidence-based medicine for clinicians to make ACS treatment choices for pregnant women with risk of giving birth between 34 (0/7) to 36(6/7) weeks gestation.
Keywords
antenatal corticosteroids; late preterm birth; short-term outcomes; preterm infants
Loading...
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
History
CURRENT STATUS: Posted
The most recent version of this article is available here.
No community comments so far
No comments provided
Version 1
Posted 24 May, 2020
No comments provided
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Maternal & Fetal Medicine
Learn more about our company.
A new preprint design is coming!
We have improved readability, clarity, accessibility, and opportunities for engagement.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Research article
Yuejun Huang
Second Affiliated Hospital of Shantou University Medical College
Corresponding Author
ORCiD: https://orcid.org/0000-0001-8240-5738
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
History
CURRENT STATUS: Posted
The most recent version of this article is available here.
No community comments so far
No comments provided
Version 1
Posted 24 May, 2020
No comments provided
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Maternal & Fetal Medicine
License:
This work is licensed under a CC BY 4.0 License. Read Full License
The most recent version of this article is available here.
Background The effects of maternal antenatal corticosteroid (ACS) treatment on the short-term outcome of late preterm infants are unclear.
Methods This is a retrospective cohort study. Data of pregnant women who gave birth between 34 (0/7) to 36 (6/7) weeks gestation from January 2014 to June 2019 were collected. Nine short-term outcomes of preterm infants from mothers who received ACS treatment were compared to preterm infants from mothers who did not receive ACS treatment.
Results The results were as follows: (1) ACS administration to pregnant women at high risk for giving birth between 34 (0/7) to 36 (6/7) weeks pregnancy, can decrease the cost and inpatient time of their infants; (2) lack of maternal ACS treatment is an independent risk factor for neonatal respiratory distress syndrome; (3) use of maternal ACS does not increase the risk of neonatal pneumonia, neonatal hypoglycemia, neonatal sepsis, necrotizing enterocolitis of newborns, neonatal intracranial hemorrhage, and hypoxic-ischemic encephalopathy in preterm infants.
Conclusions Use of ACS for pregnant women at risk for giving birth between 34 (0/7) to 36 (6/7) weeks pregnancy has more advantage than disadvantage. Our study provides evidence-based medicine for clinicians to make ACS treatment choices for pregnant women with risk of giving birth between 34 (0/7) to 36(6/7) weeks gestation.
Loading...